Browsing by Author "Parveen S."
Now showing 1 - 4 of 4
Results Per Page
Sort Options
Item Correction to: PLGA-Quercetin Nano-Formulation Inhibits Cancer Progression via Mitochondrial Dependent Caspase-3,7 and Independent FoxO1 Activation with Concomitant PI3K/AKT Suppression (Pharmaceutics, (2022), 14, 7, (1326), 10.3390/pharmaceutics14071326)(Multidisciplinary Digital Publishing Institute (MDPI), 2024) Yadav N.; Tripathi A.K.; Parveen A.; Parveen S.; Banerjee M.In the published publication [1], there was an error regarding the affiliation for Neera Yadav. In addition to affiliation 1, the updated affiliation should include: Molecular and Human Genetics Lab, Department of Zoology, University of Lucknow, Lucknow 226007, India. Neera Yadav did not act as the corresponding author any more. Shama Parveen and Monisha Banerjee (the corresponding author) were not included as authors in the original publication [1]. The corrected Author Contributions statement appears here. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated. Shama Parveen: investigation, formal analysis, methodology; Monisha Banerjee: project administration, funding acquisition, resources, supervision, writing�review and editing. The authors also acknowledge Ratan Singh Ray, CSIR-Indian Institute of Toxicology Research (IITR), Lucknow, India, for the synthesis of nanoparticles; Birbal Sahni Institute of Palaeosciences (BSIP), Lucknow, for the SEM facility; Centre of Excellence, Higher Education Government of Uttar Pradesh for the cell culture facility at the Molecular and Human Genetics Laboratory, Department of Zoology, University of Lucknow, Lucknow-226007, India. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor and Editor-in-Chief. The original publication has also been updated. � 2024 by the authors.Item Fabrication of bioactive transparent glass ceramics 55SiO2�25Na2O-(15-x)CaO�5P2O5- xZrO2 (0?x?6): Physical, structural and in vitro cell viability insights for biomedical applications(Elsevier Ltd, 2024) Shweta; Mishra R.K.; Pradhan B.L.; Parveen S.; Behera P.; Avinashi S.K.; Kumari S.; Fatima Z.; Sen P.; Kumar S.; Mishra M.; Banerjee M.; Dey K.K.; Ghosh M.; Gautam C.Zirconia (ZrO2) reinforced transparent glass ceramics (TGCs) are excellent materials for enhanced cell viability and biocompatibility for biomedical applications. Herein, ZrO2 doped SiO2�Na2O�CaO�P2O5 base compositions derived from traditional melt-quench technique. The impacts of ZrO2 on the physical, structural, optical, morphological, and biological evaluation were studied. XRD discloses the major phase formation of buchwaldite (CaNaPO4) and disodium calcium silicate (Na2CaSiO4). Density of the TGC samples was calculated and found to be in the range of 2.535�2.910 g/cm3. The optical parameters, and particle size were estimated and analyzed. Herein, ZrO2 plays a significant role as a network modifier and various bond assignments in the glassy network that confirmed by FTIR spectroscopy. Surface morphology and its elemental investigations were also studied using SEM and XPS techniques. Solid state NMR spectrum on 23Na, 29Si, and 31P nucleus were studied for various interactions. Moreover, the cell viability of the fabricated samples on the cancer cells were analyzed and resulted to possess the half maximum inhibitory concentrations (IC50) of the samples were calculated and valued to be 92 to 40 ?g/ml respectively. The sample 55SiO2�25Na2O�9CaO�5P2O5�6ZrO2 (BG4) demonstrated a remarkable biological activity for bone regeneration and implants. Further, the cell cytotoxicity was evaluated by performing trypan blue assay, DAPI and DCFH-DA staining on the TGC samples. The data assembled in this research approves the hypothesis that the TGCs represent a feasible material for the biomedical applications for bone and tooth implants. � 2024 Elsevier Ltd and Techna Group S.r.l.Item Fabrication, structural, and enhanced mechanical behavior of MgO substituted PMMA composites for dental applications(Nature Research, 2024) Kumari S.; Mishra R.K.; Parveen S.; Avinashi S.K.; Hussain A.; Kumar S.; Banerjee M.; Rao J.; Kumar R.; Gautam R.K.; Gautam C.The most common denture material used for dentistry is poly-methyl-methacrylate (PMMA). Usually, the polymeric PMMA material has numerous biological, mechanical and cost-effective shortcomings. Hence, to resolve such types of drawbacks, attempts have been made to investigate fillers of the PMMA like alumina (Al2O3), silica (SiO2), zirconia (ZrO2) etc. For the enhancement of the PMMA properties a suitable additive is required for its orthopedic applications. Herein, the main motive of this study was to synthesize a magnesium oxide (MgO) reinforced polymer-based hybrid nano-composites by using heat cure method with superior optical, biological and mechanical characteristics. For the structural and vibrational studies of the composites, XRD and FT-IR were carried out. Herein, the percentage of crystallinity for all the fabricated composites were also calculated and found to be 14.79�30.31. Various physical and optical parameters such as density, band gap, Urbach energy, cutoff energy, cutoff wavelength, steepness parameter, electron�phonon interaction, refractive index, and optical dielectric constant were also studied and their values are found to be in the range of 1.21�1.394�g/cm3, 5.44�5.48�eV, 0.167�0.027�eV, 5.68�eV, 218�nm, 0.156�0.962, 4.273�0.693, 1.937�1.932, and 3.752�3.731 respectively. To evaluate the mechanical properties like compressive strength, flexural strength, and fracture toughness of the composites a Universal Testing Machine (UTM) was used and their values were�60.3 and 101�MPa, 78 and 40.3�MPa, 5.85 and 9.8�MPa-m1/2 respectively. Tribological tests of the composites were also carried out. In order to check the toxicity, MTT assay was also carried out for the PM0 and PM15 [(x)MgO + (100 ? x) (C5O2H8)n] (x = 0 and 15) composites. This study provides a comprehensive insight into the structural, physical, optical, and biological features of the fabricated PMMA-MgO composites, highlighting the potential of the PM15 composite with its enhanced density, mechanical strength, and excellent biocompatibility for denture applications. � 2024, The Author(s).Item Salivary transforming growth factor beta in oral submucous fibrosis: A diagnostic and predictive marker(Wolters Kluwer Medknow Publications, 2024) Rai A.; Parveen S.; Shree P.; Ahmed T.; Ali S.; Kaur M.; Sircar K.; Sybil D.; Chandra A.Context: Growth factors and cytokines like transforming growth factor beta (TGF-b) play a key role in the pathogenesis of oral submucous fibrosis. Aims: To elucidate the role of Salivary TGF-b isoforms as a predictive and diagnostic marker for oral submucous fibrosis. Settings and Design: A total of 30 OSMF and 10 control patients were included in this study, and their clinic-epidemiological data was recorded. Methodology: The expression of TGF-b genes�TGF-b1, TGF-b2, TGF-b3�was studied by a real-time polymerase chain reaction in tissue and saliva. Patients were given medicinal intervention for 12 weeks along with jaw-opening exercises. Expression of salivary TGF-b genes was studied at 12 weeks. Statistical Analysis Used: SPSS software version 20. Result: Expression of salivary TGF beta isoforms in OSMF was more than in the control group. There was an increase in salivary TGF-b1, b2, b3 expressions with increasing clinical grades of OSMF and advancing the stage of the disease. Expression of all the TGF beta isoforms was decreased after treatment with statistically significant results. Statistically significant correlations were found between the mean difference of TGF-b1 and the mean difference between mouth opening and tongue protrusion. Conclusion: Salivary TGF-b isoforms may be used in diagnosis, risk assessment, and screening of the entire population at risk of OSMF after its clinical validation. However, adequate sample size and segmental assessment of the expression of TGF-b isoforms are needed for further evaluation. � 2023 Journal of Cancer Research and Therapeutics.
